Company intelligence / Profile preview

Shanghai Genomics Technology

Shanghai, Shanghai, Chinagnimission.com ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Shanghai Genomics has advanced several programs into clinical development. Its lead candidate F573 targets the caspase family and is in Phase 2 trials for acute-on-chronic liver failure. Other candidates include hydronidone targeting TGF-beta x p38 gamma for hepatitis B (pending clinical stage), and F200 targeting CDK9 for chronic obstructive pulmonary disease (pending). The company has a track record of successful drug approvals in China, including Etuary® (pirfenidone) for idiopathic pulmonary fibrosis.

Therapeutic areas: GastroenterologyPulmonologyInfectious Diseases
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Centocor/Johnson & Johnson subsidiary Centocor Inc.Inceptua GmbH

Beyond the preview

Go deeper on Shanghai Genomics Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Genomics Technology.

Explore the full profile